Für die chronische spontane Urtikaria, die auf H1-Antihistaminika nicht ausreichend anspricht, zeichnet sich mit den Bruton-Tyrosin-Kinase-Inhibitoren (BTKi) eine neue Therapieoption ab: Vielversprechende Ergebnisse wurden jetzt für den oralen reversiblen BTKi Rilzabrutinib veröffentlicht.

YouTube video by Plantão Brasil (Thiago dos Reis)

YouTube video by WhimzieCat

Chairs: Daniel Aguilar-Zapata & Amanda Ribeiro dos Santos Speaker 1 A Hoarse Voice and Thyroitoxicosis: Navigating Atypical Disseminated Fungal Infections Under BTKi Therapy Pao-Yu Chen Speaker 2...

Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple sclero...

AbstractBruton’s tyrosine kinase inhibitors (BTKi) have been associated to an increased risk of invasive fungal disease, with skin and soft tissue (SST) mucormycosis accounting for a minority of cases. We present a 72-year-old patient with chronic lymphocytic leukemia who developed necrotizing fasciitis and myositis due to Lichtheimia spp after 4 months of therapy with the second generation BTKi zanubrutinib, with a fatal outcome despite aggressive treatment. Our literature review identified seven additional cases of BTKi-associated SST mucormycosis, revealing an all-cause mortality rate of 37.5%. Two thirds of the patients had a history of previous trauma or skin lesion.Keywords: Bruton’s tyrosine kinase inhibitor; zanubrutinib; skin and soft tissue mucormycosis; infection; chronic lymphocytic leukemia

AbstractBruton tyrosine kinase inhibitors (BTKis) have been associated with an increased risk of invasive fungal disease, with skin and soft tissue mucormycosis accounting for a minority of cases. We present a 72-year-old patient with chronic lymphocytic leukemia who developed necrotizing fasciitis and myositis due to Lichtheimia spp after 4 months of therapy with the second-generation BTKi zanubrutinib, with a fatal outcome despite aggressive treatment. Our literature review identified 7 additional cases of BTKi-associated skin and soft tissue mucormycosis, revealing an all-cause mortality rate of 37.5%. Two-thirds of the patients had a previous trauma or skin lesion.

🧠Mantle Cell Lymphoma– ESMO 2025 🔬Test TP53+→ Clinical trials 🟢Asymptomatic/limited stage → Observe or treat if risk factors 🔵Symptomatic, fit →R-CHOP/R-DHAP ±Ibrutinib→ ASCT→R maintenance 🧓Unfit/older →BR, VR-CAP, R-BAC or BTKi-based ± R maintenance #MCL #Lymphoma https://t.co/itDMmVpaiR

Most patients with CLL who discontinued BTK inhibitors and later received BCL2i achieved early responses but poor long-term outcomes.